

What Is Claimed:

1. A method of treating hot flashes in a patient comprising:
providing a tachykinin receptor antagonist selected from the
5 group of NK₂ receptor antagonists and NK₃ receptor antagonist; and
administering the tachykinin receptor antagonist to a patient
experiencing hot flashes under conditions effective to treat the hot flashes.
2. The method according to claim 1, wherein the tachykinin
10 receptor antagonist is a NK₂ receptor antagonist.
3. The method according to claim 2, wherein the NK₂ receptor
antagonist is selected from the group consisting of saredutant, MEN 10627, and
combinations thereof.
15
4. The method according to claim 1, wherein the tachykinin
receptor antagonist is a NK₃ receptor antagonist.
5. The method according to claim 4, wherein the NK₃ receptor
20 antagonist is selected from the group consisting of talnetant hydrochloride, osanetant,
and combinations thereof.
6. The method according to claim 1, wherein the tachykinin
receptor antagonist comprises a combination of tachykinin receptor antagonists.
25
7. The method according to claim 6, wherein the combination of
tachykinin receptor antagonists comprises a second tachykinin receptor antagonist
selected from the group of NK₁ receptor antagonists, NK₂ receptor antagonists, and
NK₃ receptor antagonists.
30
8. The method according to claim 1, wherein the tachykinin
receptor antagonist is administered in an amount of about 10 to about 5000 mg per
day.

9. The method according to claim 1, wherein the patient is a female patient.
- 5 10. The method according to claim 9, wherein the female patient is postmenopausal.
11. The method according to claim 10, wherein menopause is drug induced, surgically induced, or naturally-occurring.
- 10 12. The method according to claim 11, wherein menopause is drug induced.
13. The method according to claim 12, wherein the drug is an anti-estrogen compound.
- 15 14. The method according to claim 13, wherein the anti-estrogen compound is tamoxifen.
- 15 15. The method according to claim 1, wherein the patient is a male patient.
16. The method according to claim 15, wherein the male patient experiences drug induced hot flashes.
- 25 17. The method according to claim 16, wherein the drug is an anti-androgen compound.
18. The method according to claim 17, wherein the anti-androgen compound is leuprolide acetate.
- 30 19. The method according to claim 1, wherein said administration is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly,

intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membranes.

5 20. The method according to claim 1, wherein the tachykinin receptor antagonist is present in a pharmaceutical composition comprising the tachykinin receptor antagonist and a pharmaceutically-acceptable carrier.

10 21. The method according to claim 20, wherein the pharmaceutical composition is in a liquid or solid dosage form.